BRCA1 and ovarian serous carcinoma: At the same time, Bi et al. observed that the PARPi, olaparib, exerted radiosensitizing effects on both BRCA1-normal and BRCA1-mutant high-grade serous ovarian carcinoma (HGSOC) cell lines in an in vitro study.